Notably, the methylation levels of the SEPT9 CpG site in CRC patients showed a sensitivity of 66.67% (95% CI, 41.71–84.82%) and a specificity of 86.67% (95% CI, 70.32–94.69%), with a cut-off > 1.56. Here, SEPTIN9 is linked to colorectal carcinoma.